Using a 14-gene test to guide chemotherapy significantly improved disease-free survival in patients with early nonsquamous ...

MAIA Biotechnology Announces Positive Efficacy Update for Phase 2 THIO-101 Clinical Trial in Non-Small Cell Lung Cancer ...

(NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted ...

A new kind of cancer treatment is emerging—one that turns the patient’s own body into a drug factory. Here's what you need to ...

AbbVie’s telisotuzumab adizutecan achieved an ORR of 63% in EGFR-mutant NSCLC patients, with current ADC options in this ...

In May, the FDA granted significant drug approvals across various therapeutic areas, marking notable progress in expanding treatment options for patients.

Patients with stage II and IIIB non-small cell lung cancer (NSCLC) with an EGFR mutation had better outcomes when treated ...

The annual meeting of the American Society of Clinical Oncology was held from May 31 to June 3 in Chicago and hosted more ...

Among the 43 evaluable patients treated with sevabertinib, the confirmed objective response rate was 72.1%.

A mother-of-two from Carlisle says she has been given her life back after receiving targeted cancer treatment.

Roche's Alecensa has been recommended for routine NHS use as an adjuvant treatment for ALK-positive non-small cell lung cancer (NSCLC), the first targeted therapy for this indication. Alecensa ...

Non-small cell lung cancer (NSCLC) accounts for the majority of lung cancer cases and remains a leading cause of cancer ...